Stock Monitor: Gilead Sciences Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=ATNM as the Company's latest news hit the wire. On February 06, 2018, the New York-based biopharmaceutical Company announced on initiation of a Phase-1, dose-escalation clinical trial to study the combination of Actimab-A with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML). Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Gilead Sciences, Inc. (NASDAQ: GILD), which also belongs to the Healthcare sector as the Company Actinium Pharma. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=GILD
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Actinium Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=ATNM
Actimab-A is Ideally Suited to be Studied in Combination with CLAG-M
Dr. Mark Berger, Chief Medical Officer of Actinium, stated that Actimab-A is ideally suited to be studied in combination with other therapeutic modalities like CLAG-M given its potency and minimal extramedullary toxicities.
He continued by stating that this novel combination is expected to demonstrate Actimab-A's key strengths through higher response rates, a greater number of patients successfully receiving a bone marrow transplant and ultimately, survival.
Dr. Mark added that it will also demonstrate the value of using Actimab-A in combinations as the Company believes that combination therapies will be the next wave in the treatment of patients with AML.
Actimab-A Plus CLAG-M Further Expands Actinium's CD33 Program
Sandesh Seth, Chairman and CEO of Actinium, mentioned that this latest clinical initiative further demonstrates that the Company is building the industry leading CD33 Program. Actinium is the only company with multi-disease, multi-indication clinical trials with its ongoing Actimab-A, Actimab-M and planned Actimab-MDS, and this latest initiative has the potential of extending the addressable patient population for Actimab-A.
Sandesh added that this is a viable approach for Actimab-A as Actinium begins to strategize and implement the next phase of Actimab-A's development.
Actimab-A Phase-2 Clinical Trial for Patients with Newly Diagnosed AML, Age 60 and Older
Actimab-A is currently being studied in Phase-2 clinical trial in patients that are newly diagnosed with AML who are over the age of 60 and that are ineligible for intense chemotherapy, also known as unfit patients. The clinical trial is active at 16 clinical trials sites. Actinium expects to complete patient enrollment of the Phase-2 trial in the first half of 2018 and report top-line data results in the second half of 2018.
FDA Approved Treatments for AML in 2017
- On August 01, 2017, FDA granted approval to Celgene Corporation's IDHIFA® (enasidenib) for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation.
- On August 03, 2017, FDA approved Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of AML, a rapidly progressing and life-threatening blood cancer.
- On September 01, 2017, FDA granted approval to Pfizer's Mylotarg™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.
About Acute Myeloid Leukemia
AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally AML spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
About Actimab-A and CLAG-M
Actimab-A is Actinium's lead drug candidate from its CD33 program and is an Antibody Radio-Conjugate (ARC) that is comprised of the CD33 targeting antibody lintuzumab and actinium-225, an alpha-emitting radioisotope. CLAG-M is a salvage chemotherapy regimen that consists of cladribine, cytarabine, and filgrastim with mitoxantrone for patients with relapsed or refractory AML.
About Actinium Pharmaceuticals, Inc.
Founded in 2000 and headquartered in New York City, New York, Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company's lead radiopharmaceutical candidate, Iomab™-B, will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
Stock Performance Snapshot
February 07, 2018 - At Wednesday's closing bell, Actinium Pharma's stock climbed 2.06%, ending the trading session at $0.65.
Volume traded for the day: 506.16 thousand shares.
Stock performance in the previous three-month period - up 2.85%; and past six-month period - up 7.79%
After yesterday's close, Actinium Pharma's market cap was at $59.01 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
